Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Oropharynx (OPX) Biomarker Trial

NCT06356272 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT06356272
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06356272 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Oropharynx (OPX) Biomarker Trial
Lead sponsor
Mayo Clinic
Phase
Observational
Overall status
Recruiting
Start date
November 15, 2019
Completion date
November 30, 2029
Enrollment
560 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

clinical stage iii hpv-mediated (p16-positive) oropharyngeal carcinoma ajcc v8, clinical stage iv hpv-mediated (p16-positive) oropharyngeal carcinoma ajcc v8, head and neck carcinoma, head and neck neoplasm, metastatic oropharyngeal squamous cell carcinoma, oropharyngeal squamous cell carcinoma, recurrent oropharyngeal squamous cell carcinoma, salivary gland neoplasms, stage iii oropharyngeal (p16-negative) carcinoma ajcc v8, stage iv oropharyngeal (p16-negative) carcinoma ajcc v8, thyroid gland neoplasm